CAS Medical Systems Inc. widened its second-quarter net loss on flat sales as the Branford biotech launches a new line of vital-signs measurement devices.
For three months ended June 30, CAS Med lost a net $2.9 million, or 22 cents a share, up from a net deficit of $1.9 million, or 15 cents a share, a year earlier.
Second-quarter sales were $5.2 million vs. $5 million a year ago.
CAS is launching its next-generation Fore-Sight Elite machine used for non-invasive measuring of patients’ blood-oxygen levels. In addition, it has federal clearance to market the 740 Select vital signs monitor.
